Veeva claims AI gets drugs to peak sales 10% faster, but its $6 billion 2030 target excludes AI
Arno Sosna pitched AI agents that get a drug to peak sales 10% faster, then told a Copenhagen audience that AI's effect on a launch's mature half is unknown. Veeva's own $6 billion 2030 target excludes AI, and the December 3 earnings are the first test of both claims.
Richard Tangthree-minute read
Veeva+1.40% — Veeva, up 1.40 percent today, whose software runs the pharmaceutical industry's commercial and clinical work, put numbers on the "agentic launch" for the first time at its Commercial Summit in Copenhagen on November 18 1. CRM suite president Arno Sosna opened with the problem Veeva sells into: 58% of drug launches miss their commercial expectations 1. A drug then needs five to seven years to reach peak sales 1.
His answer was the agentic launch: AI agents that listen to field visits, write the call reports and flag prescribing obstacles, a third commercial channel beside the rep and the website 12. Veeva claims that gets a drug to peak sales 10% faster 1. Then he cut his own claim on stage: agents help at launch, but the second half of the curve "depends on the maturity and the patent", and AI's effect on that phase, he said, remains unknown 2.
The call report is solved; the launch curve is not
The first hops of this chain are observable now. Ambient AI, listening in the room, records the visit with the doctor's consent and drafts the report itself 2. Veeva says 65% of this year's agentic call reports surfaced a treatment barrier or a commercial opening 12. Falcon MLR, built on June's Copli acquisition, pre-checks promotional content against medical, legal and regulatory rules before human review 2. It is live at more than ten biopharmas; Gilead says approvals have moved from months to days 23.
Veeva's agents write the call report now. Nobody has written the second half of the launch curve.
Finance is not counting what the stage is claiming
Veeva's finance side agrees with Sosna, in numbers. At its November 5 investor day, CFO Brian Van Wagener said the $6 billion 2030 revenue run-rate target is built from existing products and does not depend on Falcon or Vault AI 4. Vault AI is priced at 10% of the Vault subscription fee, and Falcon agents carry separate licenses 4. CEO Peter Gassner expects Falcon to start contributing revenue next year, unsized 4.
The quarter that could show any of it closed on October 31 and reports on December 3 5. Guidance puts total revenue at $932–935m 5. About $782 million of that is subscription, the recurring line AI would move first 5.
Quarterly revenue is up $311 million in three years, and AI has not yet bent the curve
- Total revenue
- Estimate
Data
| Total revenue | |
|---|---|
| Q3 '23 | $616.51M |
| Q4 '23 | $630.62M |
| Q1 '24 | $650.35M |
| Q2 '24 | $676.18M |
| Q3 '24 | $699.21M |
| Q4 '24 | $720.89M |
| Q1 '25 | $759.04M |
| Q2 '25 | $789.08M |
| Q3 '25 | $811.24M |
| Q4 '25 | $835.95M |
| Q1 '26 | $882.95M |
| Q2 '26 | $927.96M |
| Q3 '26 guide (estimate) | $932M ($932–935M) |
The sell-side split is a bet on one number
UBS cut its price target to $310 from $325 on November 19, the day after the summit, and kept its Neutral rating 6. Wells Fargo−1.33% — Wells Fargo, down 1.33 percent today holds Overweight at $400 7. Its case rests on $1 billion of recurring AI revenue by 2030 7. The two houses disagree over whether AI becomes a visible line in Veeva's revenue or stays a 10% add-on to subscriptions 7.
The sell side is $90 apart on Veeva
Data
| Value | |
|---|---|
| Close, 19 Nov | $262.92 |
| UBS, Neutral | $310 |
| Average target | $325.87 |
| Wells Fargo, Overweight | $400 |
On December 3, watch the subscription line against its guide, and whether any AI revenue is broken out at all 5. Veeva has shipped the clerical work and, inside its own 2030 target, priced the rest at zero 4. Whoever moves the second half of the curve is the builder worth paying, and that print is the first place to look.
Get Applications by email, free
How AI is changing the software people and companies use. In our daily email, every weekday.






Reader comments
0 comments